Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness

Nigel J Maclachlan, Udeni B. Balasuriya, Nancy L. Davis, Martha Collier, Robert E. Johnston, Gregory L. Ferraro, Alan J. Guthrie

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Viral diseases constitute an ever growing threat to the horse industry worldwide because of the rapid movement of large numbers of horses for competition and breeding. A number of different types of vaccines are available for protective immunization of horses against viral diseases. Traditional inactivated and live-attenuated (modified live virus, MLV) virus vaccines remain popular and efficacious but recombinant vaccines are increasingly being developed and used, in part because of the perceived deficiencies of some existing products. New generation vaccines include MLVs with deletions and/or mutations of critical genes, subunit vaccines that incorporate immunogenic proteins (or portions thereof) or expression vectors that produce these proteins as immunogens, and DNA vaccines. New generation vaccines have been developed for several viral diseases of horses. We recently have developed an alphavirus replicon-vectored equine arteritis virus (EAV) vaccine, and evaluated a commercial canary pox virus-vectored vaccine for West Nile disease. The success of these new-generation vaccines has catalyzed efforts to develop improved vaccines for the prevention of African horse sickness, a disease of emerging global significance.

Original languageEnglish (US)
Pages (from-to)5577-5582
Number of pages6
JournalVaccine
Volume25
Issue number30 SPEC. ISS.
DOIs
StatePublished - Jul 26 2007
Externally publishedYes

Fingerprint

African Horse Sickness
African horse sickness
arteritis
Arteritis
Horses
Vaccines
vaccines
horses
Virus Diseases
recombinant vaccines
West Nile Virus Vaccines
Equine Arteritis Virus
Canaries
Canarypox virus
Alphavirus
Viruses
Equine arteritis virus
Replicon
Synthetic Vaccines
Subunit Vaccines

Keywords

  • African horsesickness
  • Equine viral arteritis
  • Horse
  • Vaccines
  • West Nile

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Maclachlan, N. J., Balasuriya, U. B., Davis, N. L., Collier, M., Johnston, R. E., Ferraro, G. L., & Guthrie, A. J. (2007). Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness. Vaccine, 25(30 SPEC. ISS.), 5577-5582. https://doi.org/10.1016/j.vaccine.2006.12.058

Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness. / Maclachlan, Nigel J; Balasuriya, Udeni B.; Davis, Nancy L.; Collier, Martha; Johnston, Robert E.; Ferraro, Gregory L.; Guthrie, Alan J.

In: Vaccine, Vol. 25, No. 30 SPEC. ISS., 26.07.2007, p. 5577-5582.

Research output: Contribution to journalArticle

Maclachlan, NJ, Balasuriya, UB, Davis, NL, Collier, M, Johnston, RE, Ferraro, GL & Guthrie, AJ 2007, 'Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness', Vaccine, vol. 25, no. 30 SPEC. ISS., pp. 5577-5582. https://doi.org/10.1016/j.vaccine.2006.12.058
Maclachlan, Nigel J ; Balasuriya, Udeni B. ; Davis, Nancy L. ; Collier, Martha ; Johnston, Robert E. ; Ferraro, Gregory L. ; Guthrie, Alan J. / Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness. In: Vaccine. 2007 ; Vol. 25, No. 30 SPEC. ISS. pp. 5577-5582.
@article{fc1ba34513b349c7a0b36d2790ed8bdb,
title = "Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness",
abstract = "Viral diseases constitute an ever growing threat to the horse industry worldwide because of the rapid movement of large numbers of horses for competition and breeding. A number of different types of vaccines are available for protective immunization of horses against viral diseases. Traditional inactivated and live-attenuated (modified live virus, MLV) virus vaccines remain popular and efficacious but recombinant vaccines are increasingly being developed and used, in part because of the perceived deficiencies of some existing products. New generation vaccines include MLVs with deletions and/or mutations of critical genes, subunit vaccines that incorporate immunogenic proteins (or portions thereof) or expression vectors that produce these proteins as immunogens, and DNA vaccines. New generation vaccines have been developed for several viral diseases of horses. We recently have developed an alphavirus replicon-vectored equine arteritis virus (EAV) vaccine, and evaluated a commercial canary pox virus-vectored vaccine for West Nile disease. The success of these new-generation vaccines has catalyzed efforts to develop improved vaccines for the prevention of African horse sickness, a disease of emerging global significance.",
keywords = "African horsesickness, Equine viral arteritis, Horse, Vaccines, West Nile",
author = "Maclachlan, {Nigel J} and Balasuriya, {Udeni B.} and Davis, {Nancy L.} and Martha Collier and Johnston, {Robert E.} and Ferraro, {Gregory L.} and Guthrie, {Alan J.}",
year = "2007",
month = "7",
day = "26",
doi = "10.1016/j.vaccine.2006.12.058",
language = "English (US)",
volume = "25",
pages = "5577--5582",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "30 SPEC. ISS.",

}

TY - JOUR

T1 - Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness

AU - Maclachlan, Nigel J

AU - Balasuriya, Udeni B.

AU - Davis, Nancy L.

AU - Collier, Martha

AU - Johnston, Robert E.

AU - Ferraro, Gregory L.

AU - Guthrie, Alan J.

PY - 2007/7/26

Y1 - 2007/7/26

N2 - Viral diseases constitute an ever growing threat to the horse industry worldwide because of the rapid movement of large numbers of horses for competition and breeding. A number of different types of vaccines are available for protective immunization of horses against viral diseases. Traditional inactivated and live-attenuated (modified live virus, MLV) virus vaccines remain popular and efficacious but recombinant vaccines are increasingly being developed and used, in part because of the perceived deficiencies of some existing products. New generation vaccines include MLVs with deletions and/or mutations of critical genes, subunit vaccines that incorporate immunogenic proteins (or portions thereof) or expression vectors that produce these proteins as immunogens, and DNA vaccines. New generation vaccines have been developed for several viral diseases of horses. We recently have developed an alphavirus replicon-vectored equine arteritis virus (EAV) vaccine, and evaluated a commercial canary pox virus-vectored vaccine for West Nile disease. The success of these new-generation vaccines has catalyzed efforts to develop improved vaccines for the prevention of African horse sickness, a disease of emerging global significance.

AB - Viral diseases constitute an ever growing threat to the horse industry worldwide because of the rapid movement of large numbers of horses for competition and breeding. A number of different types of vaccines are available for protective immunization of horses against viral diseases. Traditional inactivated and live-attenuated (modified live virus, MLV) virus vaccines remain popular and efficacious but recombinant vaccines are increasingly being developed and used, in part because of the perceived deficiencies of some existing products. New generation vaccines include MLVs with deletions and/or mutations of critical genes, subunit vaccines that incorporate immunogenic proteins (or portions thereof) or expression vectors that produce these proteins as immunogens, and DNA vaccines. New generation vaccines have been developed for several viral diseases of horses. We recently have developed an alphavirus replicon-vectored equine arteritis virus (EAV) vaccine, and evaluated a commercial canary pox virus-vectored vaccine for West Nile disease. The success of these new-generation vaccines has catalyzed efforts to develop improved vaccines for the prevention of African horse sickness, a disease of emerging global significance.

KW - African horsesickness

KW - Equine viral arteritis

KW - Horse

KW - Vaccines

KW - West Nile

UR - http://www.scopus.com/inward/record.url?scp=34447105549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447105549&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.12.058

DO - 10.1016/j.vaccine.2006.12.058

M3 - Article

C2 - 17267078

AN - SCOPUS:34447105549

VL - 25

SP - 5577

EP - 5582

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 30 SPEC. ISS.

ER -